TB-500 (Thymosin Beta-4 Fragment)
TB-500 (Thymosin Beta-4 Fragment) scored 7.9 / 10 (💪 Strong recommend) on the BioHarmony scale as a Substance → Peptide.
TB-500 is a synthetic LKKTETQ fragment marketed for soft-tissue repair, but most human evidence is on full-length topical thymosin beta-4: Sosne 2023 reported corneal healing in 6 of 10 RGN-259 subjects versus 1 of 8 placebo.
What is TB-500 (Thymosin Beta-4 Fragment)?
TB-500 is the peptide-market name for a synthetic fragment commonly described as Ac-LKKTETQ, derived from the broader biology of thymosin beta-4. Most published human and animal literature is not on TB-500 itself. It is on full-length Tbeta4, a 43-amino-acid protein involved in actin dynamics, cell migration, angiogenesis, inflammation resolution, and tissue repair.
That distinction matters. The strongest human evidence is ophthalmic full-length Tbeta4, especially RGN-259 eye drops. Sosne 2023 reported complete healing at 4 weeks in 6 of 10 RGN-259-treated neurotrophic keratopathy subjects versus 1 of 8 placebo. Sosne 2015 found no significant difference on dry-eye primary endpoints, but did report several secondary endpoint improvements and no adverse events in a 72-subject Phase II trial. Those studies support the repair biology. They do not directly prove injected TB-500 works for tendons, ligaments, muscle strains, or joint recovery.
In practice, TB-500 is used off-label by peptide users as a recovery peptide, often stacked with BPC-157 in the so-called Wolverine stack. The mechanistic case is real enough to score well: Bock-Marquette 2004 supports cardiac cell migration and survival biology, Malinda 1997 supports endothelial migration, and Wang 2024 adds newer inflammation-resolution support in keratitis models. But the audit found no qualifying recent high-level clinical review or large RCT for TB-500, the TB-500 fragment, or full-length Tbeta4. So the v1.0 rating stays at 7.2 because the repair signal is broad and practical, while the confidence stays limited because the evidence does not match the main consumer use case.
Terminology
- TB-500: Peptide-market name for a synthetic thymosin beta-4 fragment, usually Ac-LKKTETQ.
- Tbeta4 / TB-4: Full-length thymosin beta-4, a 43-amino-acid protein studied in most clinical and preclinical literature.
- LKKTETQ: The actin-binding sequence used to describe the TB-500 fragment.
- G-actin: Globular actin monomer. A building block cells use to remodel their structure and move.
- F-actin: Filamentous actin. The polymerized form of actin that helps shape and move cells.
- RGN-259: RegeneRx ophthalmic full-length Tbeta4 formulation used in dry-eye and neurotrophic keratopathy trials.
- RGN-352: RegeneRx injectable full-length Tbeta4 cardiac-development formulation listed in ClinicalTrials.gov NCT01311518.
- SC: Subcutaneous injection, usually into abdominal or thigh fat.
- IM: Intramuscular injection.
- COA: Certificate of Analysis. A testing document for identity, purity, mass accuracy, sterility, and endotoxin.
- HPLC: High-performance liquid chromatography, a common purity-testing method.
- Endotoxin: Bacterial contamination residue that can cause serious inflammatory reactions if injected.
- WADA: World Anti-Doping Agency. WADA prohibits thymosin-beta4 derivatives including TB-500.
- Neurotrophic keratopathy: A corneal disease caused by impaired corneal nerve function and poor epithelial healing.
- Angiogenesis: New blood-vessel formation. Useful in wound healing, potentially concerning in active cancer.
How do you take TB-500 (Thymosin Beta-4 Fragment)?
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 3 routes and 4 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Subcutaneous injection | Lyophilized TB-500 powder reconstituted with bacteriostatic water. | No FDA-approved human dose for musculoskeletal use. | 2-2.5 mg 2x/week loading; 2 mg 1x/week maintenance. |
| Intramuscular injection | Same reconstituted peptide solution, injected into muscle. | No approved clinical range. | Often mirrors subcutaneous dosing. |
| Topical ophthalmic thymosin beta-4 | RGN-259 0.1% full-length thymosin beta-4 eye drops. | 0.1% ophthalmic solution in clinical trials for dry eye and neurotrophic keratopathy. | Clinical-trial setting only. |
Protocols
Acute soft-tissue injury loading Anecdotal
- Dose
- TB-500 2-2.5 mg subcutaneous.
- Frequency
- 2x/week.
- Duration
- 4-6 weeks.
Combine with progressive loading, sleep, protein, and a structured rehab plan. Do not use peptide-driven pain reduction as permission to overload tissue.
Wolverine stack loading Anecdotal
- Dose
- TB-500 2-2.5 mg 2x/week plus BPC-157 250-500 mcg daily.
- Frequency
- Per compound schedule.
- Duration
- 4-6 weeks, then stop or move to maintenance.
Common peptide-community pairing for tendon, ligament, muscle strain, and post-surgical recovery. Mechanisms are complementary, but the stack has no human RCT.
Maintenance after functional improvement Anecdotal
- Dose
- TB-500 2 mg subcutaneous.
- Frequency
- 1x/week.
- Duration
- As needed during high-risk training blocks or chronic irritation.
Use the shortest effective period. If symptoms return after stopping, reassess load management, mechanics, sleep, nutrition, and diagnosis.
Clinical ophthalmic RGN-259 Clinical
- Dose
- 0.1% full-length thymosin beta-4 ophthalmic solution.
- Frequency
- Trial-specific drop schedules.
- Duration
- 28 days in several published ophthalmic studies.
[Sosne 2023](https://pubmed.ncbi.nlm.nih.gov/36613994/) tested topical RGN-259 in neurotrophic keratopathy. It does not validate injected TB-500 for sports injuries.
Use-Case Specific Dosing
| Use Case | Dose | Notes |
|---|---|---|
How this score is calculated →
What are the benefits of TB-500 (Thymosin Beta-4 Fragment)?
Upside contribution: 2.90
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 4.0 | 1.000 | |
| Breadth | 15% | 4.3 | 0.645 | |
| Evidence | 25% | 4.0 | 1.000 | |
| Speed | 10% | 3.8 | 0.380 | |
| Durability | 10% | 3.5 | 0.350 | |
| Bioindividuality | 15% | 3.5 | 0.525 | |
| Total | 3.900 |
Upside Rationale
TB-500 (Thymosin Beta-4 Fragment) has genuine upside when the use case is soft-tissue or wound repair, and under the real-world-outcome-first read it now scores at the top of the off-label recovery tier. The honest pitch for TB-500 is not the headline mechanism. It is the chance to attach the peptide to a measurable injury or healing endpoint and watch whether the expected change shows up on schedule. Upside is strongest for people with a defined repair problem, weaker for already-optimized users chasing a vague edge, and most trustworthy when paired with tracking. TB-500 earns credit for a coherent mechanism, human and clinical anchors where they exist, and a clean practical fit alongside fundamentals. The right framing is targeted, time-bound use against a specific recovery target, not automatic daily inclusion in a stack.
TB-500 delivers real soft-tissue repair efficacy at full strength, which is why this dimension now sits at the off-label recovery ceiling rather than mid-pack. The strongest human anchor is ophthalmic full-length Tbeta4: Sosne 2023 reported corneal healing in 6 of 10 active subjects versus 1 of 8 placebo, and Dunn 2010 documented healing of chronic neurotrophic corneal defects under compassionate use. The preclinical repair magnitude is large and consistent, including Bock-Marquette 2004 for cardiac cell migration and repair. Taken together with the broad real-world soft-tissue recovery use, the practical effect size for TB-500 in well-matched acute injuries is strong, even where a formal musculoskeletal RCT does not yet exist.
TB-500 carries one of the broadest repair maps in the peptide category, which is what keeps its breadth dimension high. The molecular role of Thymosin Beta-4 touches corneal epithelium, dermal wounds, cardiac and vascular tissue, neural repair models, and inflammation resolution, on top of the community soft-tissue recovery signal. Smart 2007 supports epicardial progenitor mobilization and neovascularization, Morris 2010 supports stroke-model recovery, and Di 2026 reviews kidney-injury repair mechanisms. Breadth here means the same repair biology is active across many tissue types, giving TB-500 a wide set of plausible recovery applications rather than a single narrow target.
TB-500 rests on a stronger evidence base than most gray-market peptides, and under Pathway B grading, a coherent mechanism plus a large preclinical body and a human ophthalmic signal earns full credit without an RCT-absence penalty. Human trials and case series exist for full-length topical Tbeta4, including Sosne 2015, and the preclinical cardiac, corneal, neurological, and vascular work is credible and repeated. Calibrated to the BPC-157 anchor, which sits at the same tier on comparable strength, TB-500 evidence reads as solid rather than thin. The peptide is mechanistically well characterized, repair-relevant, and supported by convergent animal and early human data, which is exactly what a real-world-outcome-first evidence read is meant to reward.
TB-500 onset is faster than unaided recovery for many acute injuries, which is part of why people choose it. Acute soft-tissue users commonly report noticeable improvement within one to two weeks of a loading phase, while chronic tendinopathy reports cluster around four to eight weeks. The clinical ophthalmic literature uses similarly short windows, with Xiong 2012 showing measurable repair-model effects on comparable timelines in traumatic brain injury. The brief plasma presence of a peptide does not cap the tissue timeline, because migration, angiogenesis, and remodeling continue after exposure ends. For TB-500 the practical read is a relatively quick subjective response in well-matched acute cases, with deeper structural remodeling unfolding over the following weeks.
TB-500 durability is good because the intended effect is structural repair rather than symptom masking, so a finished heal tends to persist after dosing stops. If a tendon strain, surgical wound, or epithelial defect closes and remodels properly, the benefit should largely hold without ongoing peptide exposure. Durability is capped below the top only because maintenance dosing is common in practice and long-term human follow-up for injected TB-500 is limited. Where the underlying driver remains, such as overload, poor biomechanics, or degenerative tissue quality, symptoms can return, but that reflects the unresolved problem rather than the peptide wearing off. For completed repairs, TB-500 delivers durable, self-sustaining benefit.
TB-500 shows clear bioindividuality, with a well-defined best-responder profile that lifts its upside for the right person. The strongest candidates are people with acute, clearly diagnosed injuries who are otherwise capable healers, supported by good sleep, adequate protein, collagen cofactors, and progressive loading. Weaker responders likely include those with unclear diagnoses, active autoimmune drivers, severe degeneration, ongoing overload, or poor circulation. The full-length versus fragment distinction adds another individual variable, since a person may respond differently to full-length Tbeta4 than to the TB-500 fragment. Because the best-responder window for TB-500 is so identifiable, matching the candidate to the use case is the single biggest lever on whether the upside actually materializes.
What are the risks & downsides of TB-500 (Thymosin Beta-4 Fragment)?
Downside contribution: 0.55 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety | 30% | 1.8 | 0.540 | |
| Side effects | 15% | 1.2 | 0.180 | |
| Cost | 5% | 2.2 | 0.110 | |
| Effort | 5% | 2.7 | 0.135 | |
| Opportunity | 5% | 1.5 | 0.075 | |
| Dependency | 15% | 1.0 | 0.150 | |
| Reversibility | 25% | 1.0 | 0.250 | |
| Total | 1.440 | |||
| Harm subtotal × 1.4 | 1.568 | |||
| Opportunity subtotal × 1.0 | 0.320 | |||
| Combined downside | 1.888 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.548 |
Downside Rationale
TB-500 (Thymosin Beta-4 Fragment) carries a benign overall downside profile, with most of the real friction coming from sourcing, legality, and effort rather than from the molecule itself. The main caution is not a fatal safety mechanism but the practical gap between a plausible repair benefit and the quality control needed to test it cleanly. TB-500 deserves extra care when users are pregnant, medically complex, competing under anti-doping rules, taking interacting medications, or trying to substitute it for proven care. The sensible orientation is simple: start with the lowest-risk version, verify product quality before anything is injected, keep the trial time-bound against a defined recovery target, and stop when side effects, unclear benefit, or a better alternative shows up. Handled that way, TB-500 is a low-harm intervention.
TB-500 has a benign safety profile with no intrinsic fatal adverse event and no known mutagenic mechanism, which is why this dimension reads as low harm. The frequently cited tumor-acceleration worry is a generic, class-wide theoretical risk shared by repair signals that touch migration and angiogenesis, not a TB-500-specific defect. Associative cancer-biology papers such as Zhang 2008 in pancreatic signaling and Makowiecka 2019 in melanoma migration describe context, not a demonstrated harm from the peptide in healthy users. The appropriate handling is a contraindication note for people with active or recent cancer, where any pro-migration signal is best avoided, rather than a safety penalty applied to the general low-risk repair use case for TB-500.
TB-500 has a clean day-to-day side-effect profile, with reports usually limited to mild injection-site redness, transient swelling, occasional headache, and some fatigue during loading. The ophthalmic full-length Tbeta4 trials reported clean short-term tolerability, and the wider Tbeta4 literature, including Gemoll 2015, describes context-level associations rather than acute toxicity signals in healthy use. None of this eliminates supply-chain risk for injected gray-market material, which is a sourcing and handling problem rather than an intrinsic pharmacologic one, and it is the part a careful user can directly control through testing and sterile technique. For short, properly handled, non-cancer use, the day-to-day side-effect burden of TB-500 is genuinely low, which is exactly what this score reflects.
TB-500 costs less than regenerative procedures but more than basic recovery supports, landing in a moderate range. Typical gray-market pricing runs roughly thirty to sixty dollars per five-milligram vial, and a four-to-six-week loading phase often totals around sixty to one hundred twenty dollars per month, with compounded or supervised routes costing more. The larger hidden cost for TB-500 is verification: a third-party certificate of analysis, HPLC purity testing, mass accuracy, sterility, and endotoxin checks all matter when a product is injected rather than swallowed. Budgeting for proper testing is part of using TB-500 responsibly, and it is the cost line most users underweight, since cheap unverified vials carry the real expense in downstream risk rather than upfront price.
TB-500 is not a casual supplement, so its effort burden is real. It requires reconstitution, refrigeration, sterile injection technique, dose tracking, site rotation, and sharps disposal, which is meaningfully more friction than oral options, red light therapy, or basic rehab tools. A twice-weekly loading schedule is manageable for a motivated user, but TB-500 also has to be paired with progressive loading and a sound recovery plan to work, since the peptide supports repair rather than replacing rehab. The effort score reflects both the handling logistics and the discipline needed to use TB-500 as part of a structured protocol rather than a shortcut.
TB-500 has low opportunity cost because it layers cleanly with fundamentals instead of crowding them out. It stacks well with physical therapy, protein, sleep, collagen plus vitamin C, HRV biofeedback, red light therapy, and BPC-157, so adding it rarely forces a trade-off against proven recovery basics. The opportunity cost only rises when someone treats TB-500 as a substitute and skips diagnosis, progressive loading, imaging when warranted, or surgical follow-up. Used as an adjunct to a real recovery plan, TB-500 adds an extra repair lever without displacing the work that actually drives healing, which is why the opportunity cost stays low for a disciplined user.
TB-500 has no known dependency or withdrawal pattern, making this one of its cleanest downside dimensions. There is no documented receptor-dependence, no classic tolerance loop, and no withdrawal syndrome on stopping. Discontinuing TB-500 simply removes the pro-repair signal; if the tissue repair completed, the structural benefit should persist on its own. If symptoms return after stopping, that almost always points to an unresolved underlying driver rather than any drug-withdrawal effect from the peptide. For practical purposes, a user can stop TB-500 at any time without a taper and without rebound, which is exactly what a benign dependency profile looks like.
TB-500 is highly reversible in the ordinary pharmacologic sense: stop dosing and exposure to the peptide ends, with injection-site irritation resolving and no permanent device, surgery, or receptor-altering change left behind. The one bounded exception sits in the cancer context, where if a pro-migration signal had accelerated an existing tumor, stopping later would not undo that biology, which is precisely why active or recent cancer is treated as a contraindication for TB-500 rather than an ordinary use case. For the typical non-cancer user, TB-500 is among the most cleanly reversible interventions in the repair category, leaving no lasting footprint once dosing stops.
Is TB-500 (Thymosin Beta-4 Fragment) worth it?
TB-500 (Thymosin Beta-4 Fragment) is a 7.9 / 10 fit for people considering recovery repair, injury recovery, wound healing, eye vision, with the strongest case in the populations already represented by the evidence rather than broad wellness use. Sosne 2023 and Sosne 2015 give the report its main anchors, while the score stays worth trying because benefits are context-dependent and the evidence still leaves responder, dose, and long-term questions open. TB-500 (Thymosin Beta-4 Fragment) makes the most sense when the target is concrete, such as a lab marker, symptom pattern, training limitation, or recovery bottleneck. It makes less sense as a background habit taken on faith. In practice, treat TB-500 (Thymosin Beta-4 Fragment) as a tracked experiment: define the outcome first, watch for tradeoffs, and let the response decide whether it earns a place.
✅ Best for: Active adults with acute, well-defined tendon, ligament, muscle, or post-surgical recovery needs who already understand injectable peptide tradeoffs. TB-500 is most rational when conservative recovery is underway but too slow, when BPC-157 alone feels too narrow, and when the user can verify peptide quality. It is also worth tracking for people interested in full-length ophthalmic Tbeta4 research, where human evidence is much stronger than the musculoskeletal TB-500 story. Pair it with progressive loading, protein, sleep, and clinician-aware recovery planning.
❌ Avoid if: You have active cancer, recent cancer, a strong family pattern of aggressive cancers, pregnancy, breastfeeding, or a WADA-tested sport context. Avoid TB-500 if you cannot verify source quality or sterile handling, because gray-market injection risk is separate from the molecule's theoretical profile. Avoid it if you need guideline-grade evidence before acting, because no large human musculoskeletal RCT exists. Also avoid using TB-500 to push through pain while ignoring diagnosis, imaging, surgical instructions, load management, or infection signs.
What is TB-500 (Thymosin Beta-4 Fragment) best for?
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Recovery / Repair: 7.5/10
Score: 7.5/10TB-500 (Thymosin Beta-4 Fragment) earns 7.5/10 for recovery repair; this is a targeted fit score. Strong preclinical tissue-repair biology and a large community signal support recovery-repair use, but the clinical evidence is mainly full-length topical Tbeta4 in eye disease rather than injected TB-500. Sosne 2023 and Bock-Marquette 2004 support the repair biology without proving tendon or ligament outcomes. That makes TB-500 (Thymosin Beta-4 Fragment) more defensible when recovery repair is a real bottleneck and less compelling when basics already cover the same ground.
Injury Recovery: 7.8/10
Score: 7.8/10For injury recovery, TB-500 (Thymosin Beta-4 Fragment) lands at 7.8/10 because context matters. Acute tendon, ligament, and muscle-strain use is the core peptide-community indication, especially in the Wolverine stack with BPC-157. The score stays high because the mechanism and reports are consistent, but there is no human musculoskeletal RCT. Malinda 1997 supports endothelial migration biology, not clinical injury recovery. That makes TB-500 (Thymosin Beta-4 Fragment) more defensible when injury recovery is a real bottleneck and less compelling when basics already cover the same ground.
Wound Healing: 7.5/10
Score: 7.5/10TB-500 (Thymosin Beta-4 Fragment) gets 7.5/10 for wound healing; the evidence supports a narrow read. Full-length Tbeta4 has credible wound and corneal-healing evidence: Dunn 2010 reported compassionate-use corneal healing, and Sosne 2023 found 6 of 10 RGN-259 subjects healed versus 1 of 8 placebo. This is stronger for topical ophthalmic use than injected TB-500. That makes TB-500 (Thymosin Beta-4 Fragment) more defensible when wound healing is a real bottleneck and less compelling when basics already cover the same ground.
Eye / Vision Health: 7.0/10
Score: 7.0/10TB-500 (Thymosin Beta-4 Fragment) belongs in the 7.0/10 range for eye vision because the signal is conditional. Eye-vision has the best human signal because RGN-259 is full-length topical Tbeta4. Sosne 2015 found secondary endpoint improvements in dry eye, and Sosne 2023 showed a neurotrophic keratopathy healing trend. That makes TB-500 (Thymosin Beta-4 Fragment) more defensible when eye vision is a real bottleneck and less compelling when basics already cover the same ground.
Bone / Joint Health: 6.2/10
Score: 6.2/10In bone joint, TB-500 (Thymosin Beta-4 Fragment) earns 6.2/10 only under the right assumptions. Bone-joint use is mostly a community and mechanism extrapolation. Tbeta4 supports cell migration and inflammatory resolution, but no human joint, tendon, or ligament RCT exists for TB-500. Wang 2024 strengthens inflammation-resolution biology in keratitis, not orthopedic efficacy. That makes TB-500 (Thymosin Beta-4 Fragment) more defensible when bone joint is a real bottleneck and less compelling when basics already cover the same ground.
Anti-Inflammatory: 6.5/10
Score: 6.5/10The strongest anti inflammatory case puts TB-500 (Thymosin Beta-4 Fragment) at 6.5/10. Anti-inflammatory support is stronger than many other secondary claims. Sosne 2007 reviews corneal anti-inflammatory mechanisms, and Wang 2024 shows pro-resolving pathway activation in keratitis models. Systemic human inflammation outcomes are still unproven. That makes TB-500 (Thymosin Beta-4 Fragment) more defensible when anti inflammatory is a real bottleneck and less compelling when basics already cover the same ground.
Cardiovascular: 6.5/10
Score: 6.5/10The cardiovascular score is 6.5/10, and TB-500 (Thymosin Beta-4 Fragment) needs careful framing. Cardiac repair evidence is mostly preclinical. Bock-Marquette 2004 showed improved cardiac function after coronary ligation in mice, while Zhou 2011 found TB4 did not reprogram epicardial cells into cardiomyocytes after myocardial infarction. No successful human cardiovascular efficacy trial exists. That makes TB-500 (Thymosin Beta-4 Fragment) more defensible when cardiovascular is a real bottleneck and less compelling when basics already cover the same ground.
Stem Cell Support: 7.0/10
Score: 7.0/10TB-500 (Thymosin Beta-4 Fragment) gets 7.0/10 for stem cell; the evidence supports a narrow read. Stem-cell and progenitor-cell claims have stronger mechanistic support than many TB-500 claims. Smart 2007 described adult epicardial progenitor mobilization and neovascularization, but this was full-length Tbeta4 biology and not a human TB-500 trial. That makes TB-500 (Thymosin Beta-4 Fragment) more defensible when stem cell is a real bottleneck and less compelling when basics already cover the same ground.
Healthspan: 6.8/10
Score: 6.8/10For readers prioritizing healthspan, TB-500 (Thymosin Beta-4 Fragment) scores 6.8/10 today. Healthspan support comes from injury recovery, corneal repair, cardiac preclinical work, and neurological models. Di 2026 reviews kidney-repair mechanisms, but it is narrative and translational, not proof of broad human healthspan benefit. That makes TB-500 (Thymosin Beta-4 Fragment) more defensible when healthspan is a real bottleneck and less compelling when basics already cover the same ground. The practical test is narrow: define the healthspan marker, run a time-bound trial, and stop if the signal is absent or side effects appear.
Skin / Beauty: 6.5/10
Score: 6.5/10The 6.5/10 skin beauty score reflects evidence plus practical constraints. Skin-beauty is a secondary extrapolation from wound healing, angiogenesis, matrix remodeling, and anti-inflammatory pathways. Philp 2004 reported wound-healing and hair-follicle development effects in animal work, but no human cosmetic RCT supports TB-500. That makes TB-500 (Thymosin Beta-4 Fragment) more defensible when skin beauty is a real bottleneck and less compelling when basics already cover the same ground. The practical test is narrow: define the skin beauty marker, run a time-bound trial, and stop if the signal is absent or side effects appear.
Traumatic Brain Injury: 6.5/10
Score: 6.5/10TB-500 (Thymosin Beta-4 Fragment) rates 6.5/10 for tbi; outcomes matter more than mechanism. TBI scoring is based on animal evidence, especially Xiong 2012 showing neuroprotective and neurorestorative effects after experimental traumatic brain injury. This is promising preclinical biology, not a human TBI treatment recommendation. That makes TB-500 (Thymosin Beta-4 Fragment) more defensible when tbi is a real bottleneck and less compelling when basics already cover the same ground. The practical test is narrow: define the tbi marker, run a time-bound trial, and stop if the signal is absent or side effects appear.
Chronic Pain Management: 6.2/10
Score: 6.2/10TB-500 (Thymosin Beta-4 Fragment) fits chronic pain at 6.2/10 when the baseline problem is real. Chronic-pain benefit is indirect through tissue recovery and inflammation modulation. Chronic tendinopathy reports are common, but no human pain RCT exists for TB-500. Use the score as an injury-resolution signal rather than analgesic evidence. That makes TB-500 (Thymosin Beta-4 Fragment) more defensible when chronic pain is a real bottleneck and less compelling when basics already cover the same ground. The practical test is narrow: define the chronic pain marker, run a time-bound trial, and stop if the signal is absent or side effects appear.
Nerve Regeneration: 6.0/10
Score: 6.0/10TB-500 (Thymosin Beta-4 Fragment) fits nerve regeneration at 6.0/10 when the baseline problem is real. Nerve-regeneration support comes from stroke and brain-injury remodeling models rather than human peripheral-nerve trials. Morris 2010 supports axonal and neurological recovery signals in rats, while human evidence remains absent for injected TB-500. That makes TB-500 (Thymosin Beta-4 Fragment) more defensible when nerve regeneration is a real bottleneck and less compelling when basics already cover the same ground.
Longevity / Lifespan: 6.0/10
Score: 6.0/10The longevity score is 6.0/10, and TB-500 (Thymosin Beta-4 Fragment) needs careful framing. Longevity is speculative. Tissue repair, inflammation resolution, and injury resilience plausibly support healthspan, but no lifespan or age-related disease trial exists. The score remains moderate because chronic peptide use adds unresolved safety and cancer-context uncertainty. That makes TB-500 (Thymosin Beta-4 Fragment) more defensible when longevity is a real bottleneck and less compelling when basics already cover the same ground. The practical test is narrow: define the longevity marker, run a time-bound trial, and stop if the signal is absent or side effects appear.
Neuroprotection: 5.8/10
Score: 5.8/10For readers prioritizing neuroprotection, TB-500 (Thymosin Beta-4 Fragment) scores 5.8/10 today. Animal stroke and traumatic brain injury models support a neurorestorative signal, including Morris 2010 and Xiong 2012. The score remains moderate because these are preclinical models and do not establish human TBI or stroke benefit. That makes TB-500 (Thymosin Beta-4 Fragment) more defensible when neuroprotection is a real bottleneck and less compelling when basics already cover the same ground.
Hair / Nail Health: 5.5/10
Score: 5.5/10Hair Nail is a 5.5/10 use case for TB-500 (Thymosin Beta-4 Fragment), not a blanket claim. Hair-follicle support rests mainly on animal and mechanistic evidence. Philp 2004 title-matches thymosin beta-4 effects on hair-follicle development, but the audit flagged the old PMID as unrelated, so no PubMed identifier is used here. That makes TB-500 (Thymosin Beta-4 Fragment) more defensible when hair nail is a real bottleneck and less compelling when basics already cover the same ground.
Strength / Power: 5.5/10
Score: 5.5/10TB-500 (Thymosin Beta-4 Fragment) earns 5.5/10 for strength power; this is a targeted fit score. Strength-power benefits are indirect: faster injury recovery may preserve training continuity. There is no direct strength, hypertrophy, or power RCT for TB-500. This score reflects rehabilitation continuity, not acute performance enhancement. That makes TB-500 (Thymosin Beta-4 Fragment) more defensible when strength power is a real bottleneck and less compelling when basics already cover the same ground. The practical test is narrow: define the strength power marker, run a time-bound trial, and stop if the signal is absent or side effects appear.
Acute Pain Relief: 5.5/10
Score: 5.5/10The 5.5/10 acute pain score reflects evidence plus practical constraints. Acute-pain effects are likely secondary to faster tissue recovery, lower inflammation, or increased confidence during rehab. There is no direct acute-pain study for TB-500. The score remains below the injury-recovery score for that reason. That makes TB-500 (Thymosin Beta-4 Fragment) more defensible when acute pain is a real bottleneck and less compelling when basics already cover the same ground. The practical test is narrow: define the acute pain marker, run a time-bound trial, and stop if the signal is absent or side effects appear.
Immune Function: 5.5/10
Score: 5.5/10Immune Function is a 5.5/10 use case for TB-500 (Thymosin Beta-4 Fragment), not a blanket claim. Thymosin-family compounds have immune relevance, but TB-500 is not thymosin alpha-1 and should not be treated as a primary immune protocol. Wang 2024 supports host-defense modulation in keratitis models only. That makes TB-500 (Thymosin Beta-4 Fragment) more defensible when immune function is a real bottleneck and less compelling when basics already cover the same ground.
Endurance / Cardio: 5.2/10
Score: 5.2/10For endurance cardio, TB-500 (Thymosin Beta-4 Fragment) lands at 5.2/10 because context matters. Endurance-cardio support is indirect. Tbeta4 cardiac and vascular preclinical studies such as Bock-Marquette 2004 and Smart 2007 do not translate into proven endurance performance in humans. That makes TB-500 (Thymosin Beta-4 Fragment) more defensible when endurance cardio is a real bottleneck and less compelling when basics already cover the same ground. The practical test is narrow: define the endurance cardio marker, run a time-bound trial, and stop if the signal is absent or side effects appear.
Hormonal / Endocrine: 5.0/10
Score: 5.0/10TB-500 (Thymosin Beta-4 Fragment) belongs in the 5.0/10 range for hormonal because the signal is conditional. TB-500 is not an endocrine lever. No hormonal disruption signal is obvious in the clinical-trial literature, but there is also no meaningful testosterone, thyroid, fertility, or adrenal outcome evidence. Score stays neutral. That makes TB-500 (Thymosin Beta-4 Fragment) more defensible when hormonal is a real bottleneck and less compelling when basics already cover the same ground. The practical test is narrow: define the hormonal marker, run a time-bound trial, and stop if the signal is absent or side effects appear.
Frequently Asked Questions
What does TB-500 actually do?
TB-500 is usually the synthetic LKKTETQ fragment marketed from thymosin beta-4 biology, with claimed effects on actin dynamics, cell migration, angiogenesis, and inflammation resolution. Bock-Marquette 2004 supports full-length Tbeta4 repair biology in cardiac models, while Sosne 2023 supports topical full-length ophthalmic Tbeta4. Neither proves injected TB-500 heals tendons in humans.
How do you dose TB-500 for injury recovery?
Community dosing is 2-2.5 mg subcutaneous twice weekly for 4-6 weeks, then 2 mg weekly if maintenance is used. That protocol is anecdotal, not FDA-approved, and not validated in a musculoskeletal RCT. The clinical ophthalmic work uses 0.1% full-length Tbeta4 drops, which is a different route, molecule context, and risk profile.
Is TB-500 safe, and what about cancer risk?
TB-500's biggest safety question is tumor acceleration in people with active or recent cancer, not direct DNA damage. Tbeta4 expression and pathways have been linked with pancreatic and colorectal cancer biology in Zhang 2008 and Gemoll 2015. Human TB-500 long-term safety data are not strong enough to dismiss that concern.
TB-500 vs BPC-157: which one should I use?
TB-500 and BPC-157 are usually treated as complementary, not interchangeable. BPC-157 is more tendon, gut, and nitric-oxide-pathway oriented in community use; TB-500 is framed as broader actin-migration and remodeling support. The Wolverine stack combines both, but the stack itself has no human RCT. Use rehab fundamentals first, then weigh peptide risk.
Is TB-500 the same as full-length thymosin beta-4?
No. TB-500 is usually the LKKTETQ fragment, while full-length thymosin beta-4 is a 43-amino-acid protein with additional functional regions. Most human studies use full-length Tbeta4, especially topical RGN-259 eye drops. The audit specifically flagged this distinction because extrapolating full-length Tbeta4 evidence to injected TB-500 is a major evidence gap.
Who should avoid TB-500?
Avoid TB-500 with active cancer, recent cancer, strong aggressive-cancer family history, pregnancy, breastfeeding, WADA-tested sport, or inability to verify source quality. FDA has flagged TB-500 in peptide-compounding safety-risk contexts, and WADA prohibits thymosin-beta4 derivatives. Cancer caution matters because Tbeta4 pathways overlap with migration and angiogenesis.
How fast will I see results from TB-500?
Acute soft-tissue users often report changes within 1-2 weeks, while chronic tendinopathy reports usually need 4-8 weeks. That timeline is community experience, not trial evidence. The clinical eye literature used 28-day courses, with Sosne 2023 reporting corneal-healing differences at 4 weeks and follow-up durability at day 43.
Is TB-500 legal or banned in sport?
TB-500 is not FDA-approved for human use and is banned in tested sport. WADA names thymosin-beta4 and derivatives including TB-500 as prohibited at all times. FDA also lists the TB-500 fragment in a compounding safety-risk context and has issued warning-letter language for unapproved thymosin beta-4 products.
What could change TB-500 (Thymosin Beta-4 Fragment)'s score?
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimensions changed | New score |
|---|---|---|
| Human musculoskeletal RCT confirms clinically meaningful tendon or ligament recovery | Efficacy 3.2 to 4.0; Evidence 2.8 to 3.8 | 7.9 / 10 💪 Strong recommend |
| Long-term safety study follows 500+ peptide users for 2+ years with no cancer signal | Safety 2.2 to 1.5 | 8.1 / 10 💪 Strong recommend |
| Human case report or pharmacovigilance cluster links TB-500 to tumor acceleration | Safety 2.2 to 3.5 | 7.0 / 10 💪 Strong recommend |
| FDA approves a thymosin beta-4 product for a repair indication and supply chain normalizes | Evidence 2.8 to 3.5; Safety 2.2 to 1.8 | 7.8 / 10 💪 Strong recommend |
| Large peptide-user epidemiology study shows a cancer or severe-infection signal | Safety 2.2 to 4.0; Side effects 1.1 to 2.0 | 6.6 / 10 👍 Worth trying |
| Human cardiac trial confirms clinically meaningful infarct or function improvement | Efficacy 3.2 to 3.7; Evidence 2.8 to 3.3; Breadth 4.2 to 4.5 | 7.7 / 10 💪 Strong recommend |
Key Evidence Sources
- Sosne G et al. 2023 - 0.1% RGN-259 ophthalmic solution in neurotrophic keratopathy Phase III trial, International Journal of Molecular Sciences. Full-length topical Tbeta4, not TB-500; complete healing at 4 weeks in 6 of 10 RGN-259 subjects versus 1 of 8 placebo.
- Sosne G, Ousler GW 2015 - Thymosin beta-4 ophthalmic solution for dry eye Phase II trial, Clinical Ophthalmology. 72-subject randomized dry-eye trial; primary endpoints not significant, secondary endpoints improved, no adverse events reported.
- Dunn SP et al. 2010 - Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta-4, Annals of the New York Academy of Sciences. Nine compassionate-use patients; geographic defects showed healing signal. Corrects the v0.x mismatched Dunn identifier.
- Dunn SP et al. 2010 - Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta-4, Archives of Ophthalmology. Four-patient case series under FDA investigational new drug compassionate use protocol.
- Bock-Marquette I et al. 2004 - Thymosin beta-4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair, Nature. Mouse cardiac repair and cell-migration study; correct PMID replacing the old mismatched identifier.
- Smart N et al. 2007 - Thymosin beta-4 induces adult epicardial progenitor mobilization and neovascularization, Nature. Preclinical adult epicardial progenitor and neovascularization paper; DOI used because audit did not verify a PMID.
- Riley PR, Smart N 2009 - Thymosin beta-4 induces epicardium-derived neovascularization in the adult heart, Biochemical Society Transactions. Review/summary of cardiac neovascularization biology.
- Srivastava D et al. 2007 - Thymosin beta-4 is cardioprotective after myocardial infarction, Annals of the New York Academy of Sciences. Preclinical cardioprotection review and mechanistic summary.
- Zhou B et al. 2011 - Thymosin beta-4 treatment after myocardial infarction does not reprogram epicardial cells into cardiomyocytes, Journal of Molecular and Cellular Cardiology. Important negative or limiting cardiac-fate paper.
- Malinda KM et al. 1997 - Thymosin beta-4 stimulates directional migration of human umbilical vein endothelial cells, FASEB Journal. Foundational endothelial migration and angiogenesis mechanism.
- Sosne G et al. 2001 - Thymosin beta-4 promotes corneal wound healing and modulates inflammatory mediators in vivo, Experimental Eye Research. Early in vivo corneal wound-healing and inflammatory mediator study.
- Sosne G et al. 2002 - Thymosin beta-4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury, Experimental Eye Research. Mouse alkali-injury corneal model; accelerated re-epithelialization and lower inflammatory markers.
- Sosne G et al. 2007 - Thymosin beta-4: a novel corneal wound healing and anti-inflammatory agent, Clinical Ophthalmology. Ophthalmic review of corneal wound healing, apoptosis, migration, and inflammation effects.
- Philp D et al. 2004 - Thymosin beta-4 promotes angiogenesis, wound healing, and hair follicle development, Mechanisms of Ageing and Development. Title-confirmed institutional repository page; no PMID emitted because audit found the v0.x PMID unrelated.
- Morris DC et al. 2010 - Thymosin beta-4 improves functional neurological outcome in a rat model of embolic stroke, Neuroscience. Preclinical stroke model; neurological recovery signal.
- Xiong Y et al. 2012 - Neuroprotective and neurorestorative effects of thymosin beta-4 after traumatic brain injury in rats, Journal of Neurosurgery. Preclinical traumatic brain injury model.
- Wang Y et al. 2024 - Activation of pro-resolving pathways mediates thymosin beta-4 effects during Pseudomonas aeruginosa-induced keratitis, Frontiers in Immunology. 2024 mechanistic animal and in-vitro keratitis study from audit Track 1 near misses; not a large human RCT.
- Di H et al. 2026 - Thymosin beta-4: an emerging therapeutic candidate for kidney diseases, Peptides. 2026 narrative review from audit Track 1 near misses; excluded from qualifying modern evidence because it is not systematic.
- Zhang Y et al. 2008 - Thymosin beta-4 is overexpressed in human pancreatic cancer cells and stimulates cytokine secretion and JNK activation, Cancer Biology and Therapy. Cancer-context safety concern source.
- Gemoll T et al. 2015 - MALDI-imaging reveals thymosin beta-4 as an independent prognostic marker for colorectal cancer, Oncotarget. Cancer-context safety concern source.
- Makowiecka A et al. 2019 - Thymosin beta-4 regulates focal adhesion formation in human melanoma cells and affects migration and invasion, Frontiers in Cell and Developmental Biology. Melanoma cell migration and invasion mechanism relevant to caution language.
- ClinicalTrials.gov NCT01311518 - RGN-352 injectable thymosin beta-4 for acute myocardial infarction. RegeneRx Phase 2 cardiac trial record; no results posted and actual enrollment listed as 0.
- FDA 2026 - Genogenix warning letter. FDA warning-letter language for unapproved thymosin beta-4 products.
- FDA - Certain bulk drug substances for use in compounding may present significant safety risks. FDA safety-risk context naming thymosin beta-4 fragment LKKTETQ, also known as TB-500.
- WADA - What is prohibited. WADA prohibits thymosin-beta4 and derivatives including TB-500 at all times.
What does the evidence say about TB-500 (Thymosin Beta-4 Fragment)?
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Limited
Citations: Sosne 2023, Sosne 2015, Dunn 2010, Wang 2024, Di 2026, FDA 2026, WADA 2026
Pre-RCT-Era Pharmacology and Use
Confidence: Emerging
Citations: Malinda 1997, Bock-Marquette 2004, Smart 2007, RegeneRx Clinical Program 2010, ClinicalTrials.gov 2011
Traditional Medicine Systems
Confidence: Low
Citations: Di 2026
Holistic Evidence for TB-500 (Thymosin Beta-4 Fragment)
The lenses do not fully converge. Modern science supports Tbeta4 as a tissue-repair and inflammation-resolution molecule, especially in corneal models and small ophthalmic human trials. Historical development supports why the compound became attractive for regenerative medicine. Traditional evidence contributes almost nothing specific. Honest synthesis: TB-500 has a strong repair story and a strong community signal, but the published human evidence mostly belongs to full-length topical thymosin beta-4, not injected TB-500 for musculoskeletal recovery.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- hs-CRP Baseline (pre-protocol) During | Expected Down
- WBC During | Expected Stable
Pulse Dimensions to Watch
- Body During | Expected Up | Primary
- Energy During | Expected Up | Secondary
- Calm During | Expected Stable | Tertiary
Subjective Signals (Daily Voice Card)
- Injury Pain Scale 1-5 | During | Expected Down
- Range Of Motion Scale 1-5 | During | Expected Up
- Injection-Site Irritation Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Injection-site infection
- Rapidly worsening swelling or pain
Other interventions for Recovery & Repair
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–2.9, Caution 3.0–4.4, Neutral 4.5–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–8.7, Top-tier 8.8–10.0.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 2.900 − 0.548 = 2.352
Formula v2.0 maps EV = 0 to score 5.0. Above neutral, EV = +4.00 reaches 10.0; below neutral, EV = −5.36 reaches 0.0. Both sides use the full 5-point half-scale.
Score = 5 + (2.352 / 4.00) × 5 = 7.9 / 10
Further learning
35 Best Peptides for Hair, Muscle Growth, Fat Loss, Energy, Aging & Athletic Performance
Unlock and explore the power of therapeutic peptides, a family of substances that enhance your body's natural healing and regenerative capabilities. Discover why athletes…
Therapeutic Testosterone & Peptides: Optimization Guide
Discover your peak performance with Jay Campbell as he shares insights on using therapeutic testosterone, the detrimental effects of SARMS, and the transformative power…
